Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Synlogic Inc
(NQ:
SYBX
)
1.400
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Synlogic Inc
< Previous
1
2
Next >
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 20, 2023
Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuria
From
Synlogic, Inc.
Via
GlobeNewswire
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
March 10, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 08, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for March 9th
March 07, 2023
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 07, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Participation in Upcoming Investor and Industry Conferences
January 24, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)
January 19, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Sidoti's January Micro-Cap Conference
January 17, 2023
Via
ACCESSWIRE
Synlogic Provides Corporate Update and Outlook for 2023
January 05, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development
January 03, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study
December 15, 2022
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
November 30, 2022
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
October 18, 2022
From
Synlogic, Inc.
Via
GlobeNewswire
The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026
May 12, 2021
Via
FinancialNewsMedia
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.